Malignant melanoma.
Recent advances in our understanding of the pathology and prognosis of malignant melanoma make possible rationally designed immunotherapeutic studies. A number of immunologic studies suggest that there may be a specific immune response to melanoma-associated antigens in patients with melanoma; however, other studies have shown lack of specificity, so this issue remains to be definitively resolved. New immunotherapeutic agents, including BCG, TF, and levamisole, among others, offer the potential for improving therapy for patients.
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D002464:Cell Migration Inhibition; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007167:Immunotherapy; D007962:Leukocytes / Q000276:immunology; D007978:Levamisole / Q000627:therapeutic use; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008545:Melanoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D009163:Mycobacterium bovis; D012882:Skin Tests; D014165:Transfer Factor / Q000627:therapeutic use
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D014165:Transfer Factor; D007978:Levamisole